Login to Your Account

Reata to Get $450M Up Front in CKD Drug Deal with Abbott

By Jennifer Boggs

Friday, September 24, 2010
When Reata Pharmaceuticals Inc. closed a $78 million Series G financing in July to push its chronic kidney disease drug bardoxolone to a new drug submission, CEO Warren Huff acknowledged that the Irving, Texas-based firm was looking for commercialization help outside the U.S. (See BioWorld Today, July 12, 2010.) (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription